Abstract:Background Only a subset of patients with gastric cancer experience long-term benefits from immune checkpoint inhibitors (ICIs). Currently, there is a deficiency in precise predictive biomarkers for ICI efficacy. The aim of this study was to develop and validate a pathomics-driven ensemble model for predicting the response to ICIs in gastric cancer, using H&E-stained whole slide images (WSI). Methods This multicenter study retrospectively collected and analyzed H&E-stained WSIs and clinical data from 584 patients with gastric cancer. An ensemble model, integrating four classifiers: least absolute shrinkage and selection operator, k-nearest neighbors, decision trees, and random forests, was developed and validated using pathomics features, with the objective of predicting the therapeutic efficacy of immune checkpoint inhibition. Model performance was evaluated using metrics including the area under the curve (AUC), sensitivity, and specificity. Additionally, SHAP (SHapley Additive exPlanations) analysis was used to explain the model’s predicted values as the sum of the attribution values for each input feature. Pathogenomics analysis was employed to explain the molecular mechanisms underlying the model’s predictions. Results Our pathomics-driven ensemble model effectively stratified the response to ICIs in training cohort (AUC 0.985 (95% CI 0.971 to 0.999)), which was further validated in internal validation cohort (AUC 0.921 (95% CI 0.839 to 0.999)), as well as in external validation cohort 1 (AUC 0.914 (95% CI 0.837 to 0.990)), and external validation cohort 2 (0.927 (95% CI 0.802 to 0.999)). The univariate Cox regression analysis revealed that the prediction signature of pathomics-driven ensemble model was a prognostic factor for progression-free survival in patients with gastric cancer who underwent immunotherapy (p<0.001, HR 0.35 (95% CI 0.24 to 0.50)), and remained an independent predictor after multivariable Cox regression adjusted for clinicopathological variables, (including sex, age, carcinoembryonic antigen, carbohydrate antigen 19-9, therapy regime, line of therapy, differentiation, location and programmed death ligand 1 (PD-L1) expression in all patients (p<0.001, HR 0.34 (95% CI 0.24 to 0.50)). Pathogenomics analysis suggested that the ensemble model is driven by molecular-level immune, cancer, metabolism-related pathways, and was correlated with the immune-related characteristics, including immune score, Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data score, and tumor purity. Conclusions Our pathomics-driven ensemble model exhibited high accuracy and robustness in predicting the response to ICIs using WSIs. Therefore, it could serve as a novel and valuable tool to facilitate precision immunotherapy.

Prognostic prediction of gastric cancer based on H&E findings and machine learning pathomics

Tumor-Infiltrating Lymphocyte-Based Risk Score for Predicting Prognosis in Gastric Cancer.

A transcriptomic study for identifying cardia- and non-cardia-specific gastric cancer prognostic factors using genetic algorithm-based methods

Construction and interpretation of machine learning-based prognostic models for survival prediction among intestinal-type and diffuse-type gastric cancer patients

Identifying Prognostic Markers From Clinical, Radiomics, and Deep Learning Imaging Features for Gastric Cancer Survival Prediction

Assessment of Prognostic Prediction Models for Gastric Cancer Using Genomic and Transcriptomic Profiles

Machine Learning Models Predict the Mtor Signal Pathway-Related Signature in the Gastric Cancer Involving 2063 Samples of 7 Centers.

Pathway- and Clinical-Factor-based Risk Model Predicts the Prognosis of Patients with Gastric Cancer.

Prognostic Model Based on Immune Checkpoint Proteins Expression and Clinicopathological Factors to Predict Outcome of Patients with Gastric Cancer.

Accurate Diagnosis and Prognosis Prediction of Gastric Cancer Using Deep Learning on Digital Pathological Images: A Retrospective Multicentre Study

Preoperative Multidetector-Row Computed Tomography-Guided Prognostic Prediction for Disease-Free Survival: A Multicenter Study in Gastric Cancer

Development of a Prognostic Model for Gastric Cancer Based on Apoptosis- and Hypoxia-Related Genes: Predictive Insights into Survival and Immune Landscape

An Integrated Classifier Improves Prognostic Accuracy in Non-Metastatic Gastric Cancer

Machine Learning-Based Computational Models Derived From Large-Scale Radiographic-Radiomic Images Can Help Predict Adverse Histopathological Status of Gastric Cancer

Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer

An integrated radiopathomics machine learning model to predict pathological response to preoperative chemotherapy in gastric cancer

Use of machine learning-based integration to develop an immune-related signature for improving prognosis in patients with gastric cancer

Machine Learning Radiomics Liver Function Model for Prognostic Prediction After Radical Resection of Advanced Gastric Cancer: A Retrospective Study

Machine Learning-Based Identification of a Novel Prognosis-Related Long Noncoding RNA Signature for Gastric Cancer

Discovery of Prognostic Signature Genes for Overall Survival Prediction in Gastric Cancer

Development and Validation of Metabolism-Related Gene Signature in Prognostic Prediction of Gastric Cancer